Class-specific antibody response to Haemophilus influenzae type b capsular polysaccharide vaccine.
Class-specific antibody response to Haemophilus influenzae type b capsular polysaccharide vaccine.
复制标题
对 b 型流感嗜血杆菌荚膜多糖疫苗的类别特异性抗体反应。
DOI：
--
复制
发表时间：
1983
影响因子：
6.4
通讯作者：
A. Sutton
中科院分区：
文献类型：
--
作者：
H. Käyhty;R. Schneerson;A. Sutton
由B型流感嗜血杆菌引起的菌血症感染在1岁左右的儿童中发病率最高，此时对荚膜多糖的血清抗体应答非常低[1，3]。事实上，荚膜多糖疫苗已被证明可有效预防18个月以上但不低于18个月的疾病[1]。初步观察结果支持以下观点：合成B型流感嗜血杆菌抗体的细胞成熟缓慢，改变了免疫球蛋白类的应答分布，并特异性导致IgG抗体应答缺陷[1]。我们已经使用固相ELISA来测量14名接种荚膜多糖疫苗的婴儿和儿童的类特异性抗体应答。我们发现，在年龄小于18个月且抗体应答普遍较低的婴儿中，两名儿童的应答仅为IgG特异性，另外两名仅为IgM特异性。在一个孩子的IgG和IgM抗体反应被检测到，并在两个没有反应被检测到。在年龄较大的儿童中，所有儿童的IgG抗体都有所增加，只有两名儿童的IgM抗体也有所增加。伊加抗体在任何免疫前血清中均未检出。第一次伊加抗体反应出现在15个月大的时候，但此后很常见。这些数据未表明IgG类抗体在对荚膜多糖疫苗的抗体应答中存在特异性缺陷。
Bacteremic infections caused by H influenzae type b have their peak incidence in children around one year of age, at a time when the serum antibody response to the capsular polysaccharide is very low [1, 3]. The capsular polysaccharide vaccine has in fact been shown to be efficacious in preventing the disease above but not below the age of 18 months [1]. Preliminary observations supported the notion that slow maturation of cells that synthesize antibody to H influenzae type b altered immunoglobulin class distribution of the response and resulted specifically in a defective IgG antibody response [1]. We have used a solid-phase ELISA to measure the class-specific antibody responses in 14 infants and children vaccinated with the capsular polysaccharide vaccine. We found that, among the infants who were less than 18 months old and whose antibody response was generally low, the response was only IgG-specific in two children and only IgM-specific in two others. In one child an IgG and IgM response was detected, and in two no response was detected. Among the older children, all children showed an increase in IgG antibody; only two also had an increase of IgM antibody. IgA antibodies were not detectable in any preimmune sera. The first IgA antibody responses were seen at the age of 15 months but were common thereafter. These data do not indicate a specific defect of IgG-class antibodies in the antibody response to the capsular polysaccharide vaccine.